219 related articles for article (PubMed ID: 31663454)
1. Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.
Testi I; Pavesio C
Ther Deliv; 2019 Oct; 10(10):621-625. PubMed ID: 31663454
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
3. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
[TBL] [Abstract][Full Text] [Related]
4. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results.
Jaffe GJ; Foster CS; Pavesio CE; Paggiarino DA; Riedel GE
Ophthalmology; 2019 Apr; 126(4):601-610. PubMed ID: 30367884
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
[TBL] [Abstract][Full Text] [Related]
6. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
[TBL] [Abstract][Full Text] [Related]
7. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
Malone PE; Herndon LW; Muir KW; Jaffe GJ
Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
Mruthyunjaya P; Khalatbari D; Yang P; Stinnett S; Tano R; Ashton P; Guo H; Nazzaro M; Jaffe GJ
Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
[TBL] [Abstract][Full Text] [Related]
9. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.
Jaffe GJ
Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800
[TBL] [Abstract][Full Text] [Related]
10. Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.
Drugs R D; 2005; 6(2):116-9. PubMed ID: 15777105
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis.
Oh EK; Lee EK; Yu HG
Can J Ophthalmol; 2014 Jun; 49(3):273-8. PubMed ID: 24862774
[TBL] [Abstract][Full Text] [Related]
12. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert).
Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL
Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.
Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD
Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant.
Bollinger KE; Smith SD
Curr Opin Ophthalmol; 2009 Mar; 20(2):99-103. PubMed ID: 19248312
[TBL] [Abstract][Full Text] [Related]
16. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.
Callanan DG; Jaffe GJ; Martin DF; Pearson PA; Comstock TL
Arch Ophthalmol; 2008 Sep; 126(9):1191-201. PubMed ID: 18779477
[TBL] [Abstract][Full Text] [Related]
17. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
18. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.
Jaffe GJ; Ben-Nun J; Guo H; Dunn JP; Ashton P
Ophthalmology; 2000 Nov; 107(11):2024-33. PubMed ID: 11054326
[TBL] [Abstract][Full Text] [Related]
19. Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management.
Brumm MV; Nguyen QD
Int J Nanomedicine; 2007; 2(1):55-64. PubMed ID: 17722513
[TBL] [Abstract][Full Text] [Related]
20. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
Chieh JJ; Carlson AN; Jaffe GJ
Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
